ATE236993T1 - Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper - Google Patents

Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper

Info

Publication number
ATE236993T1
ATE236993T1 AT95938608T AT95938608T ATE236993T1 AT E236993 T1 ATE236993 T1 AT E236993T1 AT 95938608 T AT95938608 T AT 95938608T AT 95938608 T AT95938608 T AT 95938608T AT E236993 T1 ATE236993 T1 AT E236993T1
Authority
AT
Austria
Prior art keywords
von willebrand
willebrand factor
monoclonal antibodies
directed against
antibodies directed
Prior art date
Application number
AT95938608T
Other languages
English (en)
Inventor
Mitsuyo Nagano
Hiroshi Yamamoto
Morikazu Kito
Ryota Yoshimoto
Tsuyoshi Kobayashi
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Application granted granted Critical
Publication of ATE236993T1 publication Critical patent/ATE236993T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT95938608T 1994-11-30 1995-11-29 Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper ATE236993T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29707094 1994-11-30
PCT/JP1995/002435 WO1996017078A1 (en) 1994-11-30 1995-11-29 Antithrombotic agent and anti-von willebrand factor monoclonal antibodies

Publications (1)

Publication Number Publication Date
ATE236993T1 true ATE236993T1 (de) 2003-04-15

Family

ID=17841828

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95938608T ATE236993T1 (de) 1994-11-30 1995-11-29 Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper

Country Status (13)

Country Link
US (3) US5916805A (de)
EP (1) EP0795608B1 (de)
JP (1) JP3331377B2 (de)
KR (1) KR100406072B1 (de)
CN (1) CN1254275C (de)
AT (1) ATE236993T1 (de)
DE (1) DE69530316T2 (de)
DK (1) DK0795608T3 (de)
ES (1) ES2197210T3 (de)
FI (1) FI119734B (de)
NO (1) NO319738B1 (de)
PT (1) PT795608E (de)
WO (1) WO1996017078A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017078A1 (en) 1994-11-30 1996-06-06 Ajinomoto Co., Inc. Antithrombotic agent and anti-von willebrand factor monoclonal antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
JP2002529373A (ja) 1998-10-23 2002-09-10 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド コンホメーション特異的抗ｖｏｎＷｉｌｌｅｂｒａｎｄ因子抗体
CN1198198C (zh) * 2001-02-27 2005-04-20 索尼公司 字符输入方法及字符输入装置
JP2005298336A (ja) * 2002-01-29 2005-10-27 Ajinomoto Co Inc 炎症性疾患治療用薬剤
US20050136056A1 (en) * 2002-07-29 2005-06-23 Shunsuke Kageyama Pharmaceutical composition for the treatment of thrombocytopenia
WO2004011030A1 (ja) * 2002-07-29 2004-02-05 Ajinomoto Co., Inc. 血小板減少症治療用医薬組成物
AU2003251238A1 (en) * 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP2284192A3 (de) * 2002-11-08 2011-07-20 Ablynx N.V. Antikörper aus Camelidae zur sublingualen Verabreichung
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
EP1558647B1 (de) * 2002-11-08 2015-06-10 Ablynx N.V. Einzeldomaene antikörpern gegen tnf-alpha und ihre verwendungen
NZ576284A (en) * 2003-01-10 2010-07-30 Ablynx Nv Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
CN1323713C (zh) * 2003-07-07 2007-07-04 张新侯 可溶性p－选择素及炭疽致死毒素的新用途
JP2008512097A (ja) * 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
JP2008512098A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
CA2593328C (en) 2005-01-14 2018-02-06 Ablynx N.V. Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between von willebrand factor (vwf) and platelets
MX2007014564A (es) 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
EP1918302A3 (de) * 2006-05-18 2009-11-18 AvantGen, Inc. Verfahren zur Identifikation und Isolation von epitopspezifischen Antikörpern
US8669045B2 (en) 2007-02-13 2014-03-11 Ajinomoto Co., Inc. Method for inactivating viruses with slightly acidic arginine
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
CA2718081A1 (en) * 2008-03-21 2009-09-24 Ablynx Nv Von willebrand factor specific binders and methods of use therefor
CN102089319B (zh) 2008-05-08 2013-11-13 味之素株式会社 蛋白质的重折叠方法
CN102532316B (zh) * 2010-12-24 2014-06-18 神州细胞工程有限公司 一种抗vWF单克隆抗体及其应用
CN107365388B (zh) 2011-06-23 2021-05-14 味之素株式会社 多聚体蛋白的制备方法
ES2670991T3 (es) * 2013-12-18 2018-06-04 Siemens Healthcare Diagnostics Inc. Detección de enfermedad endotelial
WO2015158851A1 (en) * 2014-04-16 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
BR112021026410A2 (pt) 2019-07-01 2022-02-08 Tonix Pharma Ltd Anticorpos anti-cd154 e usos dos mesmos
US20230001137A1 (en) * 2019-12-12 2023-01-05 Corning Incorporated Light-diffusing element configured to affect thrombi formation on intravenous catheter
JP2024503625A (ja) 2021-01-06 2024-01-26 トニックス ファーマ リミテッド 改変された抗ｃｄ１５４抗体により免疫寛容を誘導する方法
WO2025248134A1 (en) 2024-05-31 2025-12-04 Tonix Pharma Limited Treatment methods comprising administration of modified cd154 antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202264A (en) * 1989-10-27 1993-04-13 Health Research, Incorporated ELISA using multi-species antibodies for detection of von Willebrand factor in multiple species
US5342830A (en) * 1990-11-16 1994-08-30 Cor Therapeutics, Inc. Antithrombosis agents
WO1996017078A1 (en) * 1994-11-30 1996-06-06 Ajinomoto Co., Inc. Antithrombotic agent and anti-von willebrand factor monoclonal antibodies
AU724579B2 (en) 1996-04-01 2000-09-28 Sankyo Company Limited Anti-Fas recombinant antibodies and DNA therefor

Also Published As

Publication number Publication date
JP3331377B2 (ja) 2002-10-07
DK0795608T3 (da) 2003-07-21
DE69530316T2 (de) 2004-02-12
KR100406072B1 (ko) 2004-03-30
US6280731B1 (en) 2001-08-28
EP0795608A1 (de) 1997-09-17
CN1254275C (zh) 2006-05-03
FI972279A0 (fi) 1997-05-29
US5916805A (en) 1999-06-29
PT795608E (pt) 2003-08-29
WO1996017078A1 (en) 1996-06-06
EP0795608B1 (de) 2003-04-09
FI972279L (fi) 1997-07-29
NO319738B1 (no) 2005-09-12
ES2197210T3 (es) 2004-01-01
US20020028204A1 (en) 2002-03-07
NO972253D0 (no) 1997-05-16
NO972253L (no) 1997-07-29
US6793920B2 (en) 2004-09-21
EP0795608A4 (de) 2001-11-28
FI119734B (fi) 2009-02-27
DE69530316D1 (de) 2003-05-15
CN1174575A (zh) 1998-02-25

Similar Documents

Publication Publication Date Title
DE69530316D1 (de) Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
SE8700499D0 (sv) Novel pharmacologically active compounds
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
ATE230588T1 (de) Nicht-aerosol rasiergel
ATE283704T1 (de) Pharmazeutische zusammensetzungen enthaltend cs- 866 und insulinresistenz verbesserndem mitteln und deren verwendung zur behandlung von arteriosklerose und xanthom
IT1281188B1 (it) Composizione per prevenire e trattare infiammazioni con immunoglobulina a.
FR2656214B1 (fr) Cadre dynamique d'osteosynthese du rachis.
SE9401540D0 (sv) Munhygienkomposition
BR9509975A (pt) Formulação farmacêutica
DE60237447D1 (de) Verwendung von polyklonalen anti-hiv ziegenseren als therapeutisches mittel
SE8400723D0 (sv) Farmaceutisk komposition
KR930019224A (ko) 유산 위험 치료제
DE69422615D1 (de) Fibrinogenrezeptorantagonisten
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
DK0437225T3 (da) Topiske præparater
FI883723A7 (fi) Ihmisen monoklonaaliset vasta-aineet ja niitä vaikuttavana aineosana s isältävät terapeuttiset aineet infektiotauteja vastaan
FR2714603B1 (fr) Composition dermatologique et son utilisation pour la préparation d'un médicament.
CA2206423A1 (en) Antithrombotic agent and anti-von willebrand factor monoclonal antibodies
ATE25195T1 (de) Verwendung von d,l- und d-carazolol zur herstellung von antiglaukommitteln sowie arzneimittel, die d-carazolol enthalten.
KR920700029A (ko) 상피소체 고혈압성 인자(parathyroid hypertensive factor)
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
DK0663832T3 (da) Anvendelse af 4'-iod-4'-deoxydoxorubicin til behandling af amyloidose
DE59107240D1 (de) Emulgatorfreie Emulsionspolymere in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe und ihre Herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0795608

Country of ref document: EP